SGLT2 Inhibitors: A Novel Pharmacological Approach in Heart Failure Treatment?
Learn about the correlation between diabetes and heart failure and the use of SGLT-2 inhibitors as a potential treatment option. Stay updated with the latest evidence on managing heart failure patients.
About this course
Diabetes and heart failure are two diseases that are highly correlated. Until recently, antidiabetic agents either had a neutral effect or possible harm with regard to cardiovascular outcomes. Sodium-glucose cotransporter-2-inhibitors are the latest class of drugs for hyperglycemic management in patients with T2DM. A serendipitous benefit of decreased risk of heart failure hospitalization was discovered and emerging evidence suggests that benefit extends to people without diabetes and in patients with heart failure with preserved ejection fraction. Despite the benefit shown in clinical trials, clinicians should be mindful of the adverse effects of these agents as a class and weigh the risk versus benefit for each patient. This activity will focus on current evidence of using SGLT-2 inhibitors for patients with heart failure.
Course Accreditation
This course is approved for the following professions. You can get more details on each profession by clicking on it.
Faculty
InstructorsYou might also be interested in
What are others saying?
Take a look at what other healthcare professionals are saying about AchieveCE’s continuing education courses.
Requirements
Participants must score a passing grade of 70% or higher on the activity post-test and complete an activity evaluation. There are no time limits and unlimited test-taking attempts. Credits will be reported automatically to CE Broker if your license information is entered properly in your profile.
- Windows 8.1
- Windows 10
- Mac OS X 10.1+
- iOS 10+
- Android 4.3+
- Google Chrome
- Microsft Edge
- Mozilla Firefox
- Adobe Acrobat Reader
- Broadband Internet Connection: T1
- Hi-speed DSL or Cable4G cellular connection